In observance of World TB Day I am pleased to announce the next session of CDC’s Public Health Grand Rounds, entitled TB & HIV: A Deadly Duo which will be held on Thursday, March 24 at 11 a.m. (EDT).
As we commemorate Dr. Robert Koch’s 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB, we are reminded of the many advances over the past 129 years in TB control. Through the intervention efforts of CDC, USAID, WHO’s Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995.
In spite of these successes, TB still remains a serious threat, especially for those infected with HIV. HIV is the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB.
World TB Day presents CDC and its partners with a prime opportunity to discuss TB/HIV-related problems and solutions while renewing our support for worldwide TB control efforts. This special session of Public Health Grand Rounds seeks to dispel myths and misconceptions about TB and HIV, discuss actions needed to reduce the spread and burden of TB, and advance our efforts in preventing deaths from TB/HIV.
Future Grand Rounds topics include sodium reduction, Lyme disease, and child maltreatment. All CDC employees and contractors are encouraged to attend these informative sessions.
Thomas R. Frieden, M.D., M.P.H.
Director, CDC, and
CDC’s Public Health Grand Rounds Presents:
TB & HIV: A Deadly Duo
Thursday, March 24, 2011
11 a.m. – 12 p.m., E.D.T.
Global Communications Center (Building 19)
Jay Varma, M.D.
Chief, International Emerging Infections Program - China
Division of Global Disease Detection and Response, Center for Global Health, CDC
Presentation: TB and HIV: Friends With(out) Benefits
Kevin Cain, M.D.
Chief, TB/HIV Team, International Research and Programs Branch,
Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention, CDC
Presentation: You Have to Find TB to Treat TB
Taraz Samandari, M.D., Ph.D.
Chief, Epidemiology Branch,
Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Elimination, CDC
Presentation: If Finding TB is so Difficult, Why Not Just Prevent It?
Mario Raviglione, M.D.
Director, STOP TB Department, World Health Organization (WHO)
Presentation: From Science to Policy to Impact
Thomas R. Frieden, M.D., M.P.H.
Presentation: Fundamentals are Fundamental
Tanja Popovic, M.D., Ph.D., Scientific Director, Public Health Grand Rounds
Shane Joiner, Communication Manager, Public Health Grand Rounds
For those unable to attend the event, the session will be available on IPTV and Envision. If you wish to join by Envision, schedule room and Envision at http://crss.cdc.gov or by using your local room scheduling process, and schedule Envision at this link: http://intraspn.cdc.gov/wagg/ITSOCustomerService/envision.aspx
For more information on Grand Rounds or World TB Day, please visit:
World TB Day
Live and Archived webcasts of Public Health Grand Rounds:
For those outside of the CDC firewall, a live external webcast is also available at: www.cdc.gov/about/grand-rounds . Presentations are archived and posted 48 hours after each session. For questions or comments, please email firstname.lastname@example.org
*Grand Rounds is now available for Continuing Education (CE) credits:
ALL Continuing Education credits/contact hours for PHGR are issued online through the CDC/ATSDR Training & Continuing Education Online system, http://www2a.cdc.gov/TCEOnline . If you have questions, call Learner Support at 1-800-418-7246 (1-800-41TRAIN), or email@example.com .
Those who attend PHGR either in person, Envision, IPTV, or “web on demand” (www.cdc.gov/about/grand-rounds ), and who wish to receive Continuing Education must complete the online seminar evaluation. Thirty days from the initial seminar the course number will change to WD1640 and will be available for continuing education until January 21, 2012. The course code for PHGR is PHGR10.
Target Audience: Physicians, nurses, epidemiologists, pharmacists, veterinarians, certified health education specialists, laboratorians, others
- List key measures of burden of disease involving morbidity, mortality, and/or cost.
- Describe evidence-based preventive interventions and the status of their implementations.
- Identify one key prevention science research gap.
- Name one key indicator by which progress and meeting prevention goals is measured.
CE certificates can be printed from your computer immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the TCE Online System will be maintained for each user. We hope that this will assist CDC staff to fulfill the requirements for their professional licenses and certificates.
For Continuing Medical Education for Physicians (CME):
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Education designated for Non-Physicians:
Non-physicians will receive a certificate of participation.
For Continuing Nursing Education for Nurses (CNE):
The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity provides 1.0 contact hours.
For Continuing Education Contact Hours in Health Education (CECH):
Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I CECH in health education. CDC provider number GA0082.
IACET Continuing Education Units (CEU):
The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer 0.1 ANSI/IACET CEU's for this program.
For Continuing Pharmacy Education (CPE):
(For EV1640-live course)
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 1.0 Contact Hours in pharmacy education. The Universal Activity Number is 0387-0000-09-031-L04-P.
(For WD1640-Web on demand)
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 1.0 Contact Hours in pharmacy education. The Universal Activity Number is 0387-0000-09-031-H04-P.
Course Category: This activity has been designated as Knowledge-based.
There is no cost for this program.
In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use. CDC, our planners, and the presenters for this seminar do not have financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. This presentation does not involve the unlabeled use of a product or product under investigational use. There was no commercial support for this activity.